tbuckley/cabot-search huggingface dataset:
SP0195 New Imaging Modalities for RA Remission – Is Rheumatology Ready to Include Advanced Multi Parametric Imaging into the Clinical Remission Criterias?
Authors: M. Boesen
Journal: Annals of the Rheumatic Diseases (2015)

Imaging remission has for several years played a key role in the clinical treatment surveillance and disease control in oncology, and as rheumatoid arthritis share several similarities to a local cancer, a similar strategy could potentially aid to obtain faster disease control and visualisation of local inflammation suppression than clinical measures alone. An imaging guided remission strategy in patients with rheumatoid arthritis (RA) is supported in two recent reviews from 2012 and 2014, summing the latest findings in this field, where several studies, have shown that modern imaging, especially ultrasound and MRI can detect a relative large subgroup of RA patients in clinical remission who have subclinical inflammations, and that these patients subsequently have a high probability of continuous structural joint damage. These findings have already been acknowledged and included in the EULAR 2013 recommendations for the use of imaging of the joints in the management of RA, but it is still not known whether a more aggressive imaging guided treatment regime in these patients provides better disease control and prevention of structural joint progression than the treat-to-target approach where the cornerstone is fast step-up in both DMARDS and potential biologics guided by clinical measures. These questions are explored in several on-going randomized controlled multicentre studies. Another potential important area for imaging guided remission control could be monitoring of discontinuation of biologic therapy, where a recent ultrasound study showed promising results regarding prediction of both flares and absent of flares, but we await more results from on-going studies. Finally newer imaging modalities such whole-body MRI, dynamic contrast enhanced MRI, diffusion weighted MRI, and PET/SPECT CT-scans or combination of these are emerging and might also ad important information in the above mentioned areas. The presentation is divided into 3 parts: Current accepted and used remission criteria9s Recent studies using RAMRIS and Ultrasound remission criteria9s - pros and cons Future perspectives using novel promising imaging approaches like whole-body MRI, Dynamic contrast enhanced MRI (DCE-MRI), MR-Diffusion, PET and SPECT-CT <h3>Disclosure of Interest</h3> M. Boesen Grant/research support from: ESAOTE, Genoa Italy, Consultant for: Imageanalysis ltd, London, United Kingdom
Pneumonia in Children Presenting to the Emergency Department With an Asthma Exacerbation
Authors: Todd A. Florin, Hannah Carron, Guixia Huang, Samir S. Shah, Richard Ruddy, Lilliam Ambroggio
Journal: JAMA Pediatrics (2016)

Asthma and pneumonia are 2 of the most common reasons children visit the emergency department. 1 These conditions have overlapping features and can occur concomitantly.Subsequently, physicians often obtain chest radiographs to diagjamapediatrics.com
Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages
Authors: CF Perno, DA Cooney, WY Gao, Z Hao, DG Johns, A Foli, NR Hartman, R Calio, S Broder, R Yarchoan
Journal: Blood (1992)
Oncogeriatrics joint consultations: When pharmacists improve patients' management together with oncogeriatrics physician.
Authors: Jean-Baptiste Rey, Damien Parent, Stephane Perin
Journal: Journal of Clinical Oncology (2014)

79 Background: Elderly patients often have several diseases and therefore polymedicated. Comorbidities and treatments may interfere with management of oncological patients. Methods: The objectives of this project are 1) to ensure a proper understanding of patients regarding their treatment, 2) to perform a pharmaceutical analysis of patients’ prescription, 3) to propose changes to the patients’ doctors (general practitioners and physicians of the Institute) to prevent and reduce adverse drug events. The project combines medical and pharmaceutical expertise around the patient to optimize their care coordinated with the action of a "disease professional” and a "drug professional " with a particularly vulnerable population. Results: Since the project began, more than 100 patients benefited from these joint consultations, thus establishing a network between the Institute and the general practionners supporting our patients. Optimization of drug treatment and reduction of iatrogenic events avoids the complications and hospitalizations extensions and / or re-hospitalization. The pharmaceutical intervention documented in the medical records of patients (explaining terms of the intervention) and the transmission of the report to "pharmaceutical consultation" to physician 1) improves the management of patients (reduction potential iatrogenic events – e.g. risk of falling by orthostatic hypotension) and 2) allows the referring physician to optimize patient care. Conclusions: Launched in 2010, the project entered its fourth year of existence and continues.
Preventive Mental Health Programming for a Non-Health Agency
Authors: Scott H. Nelson, Paul B. Batalden, David P. Kraft, Frederick J. Stoddard
Journal: American Journal of Psychiatry (1974)

To introduce and maintain a preventive mental health program in a federal agency such as Job Corps has special requirements: a recognition of the goals of the organization, selection of personnel on the basis of proved past experience or special talent, and responsiveness to the youthful high-risk minority population the agency serves and to the staff that works with them. This paper describes how the authors attended to these requirements and developed a meaningful and effective mental health program.
LEF-1 and TCF-1 orchestrate TFH differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6
Authors: Youn Soo Choi, Jodi A Gullicksrud, Shaojun Xing, Zhouhao Zeng, Qiang Shan, Fengyin Li, Paul E Love, Weiqun Peng, Hai-Hui Xue, Shane Crotty
Journal: Nature Immunology (2015)
AB0154 Comparison of Fetuin-A and Transforming Growth Factor Beta 1 Levels in Patients with Spondyloarthropathies and Rheumatoid Arthritis
Authors: H. Harman, I. Tekeoğlu, G. Gürol, M.S. Sağ, E. Karakeçe, I.H. Çiftçi, A. Kamanlı, K. Nas
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> New bone formation plays an important role in the progression of inflammatory lesions in inflammatory rheumatic diseases. In recent literature, the question of which molecules to use for estimating new bone formation is a particularly interesting research topic. Fetuin-A and transforming growth factor beta 1 (TGFβ1) have been studied in many diseases, including metabolic, cardiovascular, and neoplastic diseases. <h3>Objectives</h3> We investigated the serum TGFβ1 and fetuin-A levels, and determined the relationships between these biomarkers and disease activity, mobility, and radiologic progression in patients with SpA and RA. <h3>Methods</h3> The study included 55 patients with SpA and 38 patients with RA, together with 28 healthy subjects. In AS patients, we assessed disease activity using the Bath AS disease activity index (BASDAI), functional ability using the Bath AS functional index (BASFI), and mobility using the Bath AS metrology index (BASMI), radiologic progression using the Bath Ankylosing Spondylitis Radiology Index (BASRI). Serum feutin-A and TGFβ1 were determined using enzyme-linked immunosorbent assay (ELISA) equipment <h3>Results</h3> Fetuin-A was significantly higher in the axial SpA and RA groups than in healthy subjects (p&lt;0.01). Serum TGFβ1 and fetuin-A levels were similar in the peripheral SpA group and in healthy subjects. A significant positive correlation was found between the fetuin-A and TGFβ1 levels in the axial SpA, peripheral SpA, and RA groups (r =0.293, p=0.009; r =0.215, p=0.04; r =0.223, p=0.05, respectively). Significant correlations were found between fetuin-A and the BASMI and BASRI values in the axial SpA patients (r =0.244, p=0.031; r =0.416, p&lt;0.001, respectively). There were no correlations of TGFβ1 or fetuin-A levels with CRP, ESR, or all of the clinical parameters in the peripheral SpA and RA patients (p&gt;0.05). <h3>Conclusions</h3> In conclusion, high levels of fetuin-A and TGFβ1 in patients with axial SpA indicate that fetuin-A could be used as a marker for bone proliferation. We hypothesize that fetuin-A may be one of the possible active steps in new bone formation. The data obtained in the present study will contribute to identifying differences between RA and SpA, and in clarifying the disease process, thereby helping to identify specific therapeutic targets. <h3>Disclosure of Interest</h3> None declared
Impact of the Nordic hamstring and hip extension exercises on hamstring architecture and morphology: implications for injury prevention
Authors: Matthew N Bourne, Steven J Duhig, Ryan G Timmins, Morgan D Williams, David A Opar, Aiman Al Najjar, Graham K Kerr, Anthony J Shield
Journal: British Journal of Sports Medicine (2016)

<h3>Background</h3> The architectural and morphological adaptations of the hamstrings in response to training with different exercises have not been explored. <h3>Purpose</h3> To evaluate changes in biceps femoris long head (BF<sub>LH</sub>) fascicle length and hamstring muscle size following 10-weeks of Nordic hamstring exercise (NHE) or hip extension (HE) training. <h3>Methods</h3> 30 recreationally active male athletes (age, 22.0±3.6 years; height, 180.4±7 cm; weight, 80.8±11.1 kg) were allocated to 1 of 3 groups: (1) HE training (n=10), NHE training (n=10), or no training (control, CON) (n=10). BF<sub>LH</sub> fascicle length was assessed before, during (Week 5) and after the intervention with a two-dimensional ultrasound. Hamstring muscle size was determined before and after training via MRI. <h3>Results</h3> Compared with <i>baseline</i>, BF<sub>LH</sub> fascicles were lengthened in the NHE and HE groups at <i>mid-training</i> (d=1.12–1.39, p&lt;0.001) and <i>post-training</i> (d=1.77–2.17, p&lt;0.001) and these changes did not differ significantly between exercises (d=0.49–0.80, p=0.279–0.976). BF<sub>LH</sub> volume increased more for the HE than the NHE (d=1.03, p=0.037) and CON (d=2.24, p&lt;0.001) groups. Compared with the CON group, both exercises induced significant increases in semitendinosus volume (d=2.16–2.50, ≤0.002) and these increases were not significantly different (d=0.69, p=0.239). <h3>Conclusion</h3> NHE and HE training both stimulate significant increases in BF<sub>LH</sub> fascicle length; however, HE training may be more effective for promoting hypertrophy in the BF<sub>LH</sub>.
THU0074 Transcription Factor SOX5 is an Essential Regulator of Rankl Expression in Synovial Fibroblast Contributing to Bone Erosion in Experimental Arthritis Model
Authors: W. Tan, X. Feng, Y. Shi, L. Xu, F. Wang, M. Zhang
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> SOX5 is a member of Sex determining region Y (SRY) box (SOX) family gene and function as transcription factors, playing important roles in the regulation of embryonic development, cell fate, and chondrogenesis.We previously reported a RANKL promoter SNP confers an elevated promoter activity after stimulation via binding to transcription factor SOX5 and is associated with younger age at onset of Rheumatoid arthritis (RA). To date, littke is known of SOX5 in RA. Here, we hypothesis that transcription factor Sox5 may be important transcriptional regulators of the RANKL gene in RA synovial fibroblast (SF). <h3>Objectives</h3> To examine the expression of SOX5 in RA patients and to elucidate their potential role in RA pathogenesis. <h3>Methods</h3> SOX expression levels in PBMC, plasma, and synovium were tested using RT-PCR, ELISA and immunohistochemistry. The interaction of SOX5 and RANKL in RA synovial fibroblast (RASF) was determined by double-immunofluorescence and immunoprecipitation. The effect of SOX5 on RANKL expression in RASF and joints was performed by lentiviral vector-mediated transfer of SOX5 cDNA or short hairpin RNA <h3>Results</h3> Among the tested 9 SOX family genes, expression of SOX5 were robust in 20 RA synovium samples. Compared to 20 osteoarthritis (OA) and 20 healthy controls (HC) samples, increased expression of SOX5 were observed consistently in synovium (p=0.01), synovial fluid and plasma (p=0.02 and p=0.001, respectively) from RA patients. SOX5 could be co-immunoprecipitated with Mab specific to RANKL upon TNFα and IL6 stimulation of rheumatoid fibroblast-like synoviocytes MH7A. Overexpression SOX5 resulted in a significantly increased RANKL level in MH7A. Transfection with SOX5 -shRNA markedly downregulated IL6 -mediated RANKL upregulation in MH7A. Intra-articular injection of lentivirus expressing shRNA for silencing SOX5 gene could significantly ameliorated clinical symptoms and bone erosion in in DAB/1mice of a CIA in part by suppression RANKL pathway. <h3>Conclusions</h3> These data support the hypothesis that transcription factor Sox5 in important transcriptional regulators of the RANKL gene in synovial fibroblast and may provide novel therapeutic targets for inhibiting RANKL expression. <h3>References</h3> Tan W, Wu H, Zhao J, Derber LA, Lee DM, Shadick NA et al. A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. Arthritis Rheum 2010; 62(10):2864-75. <h3>Disclosure of Interest</h3> None declared
SAT0417 Cancer and Primary SjÖgren Syndrome in 1216 Patients (GEAS-SS Registry): Systemic Activity Measured by the Essdai is Related to Hematological, but not Solid Neoplasia
Authors: P. Brito Zeron, B. Kostov, R. Solans, G. Fraile, A. García-Pérez, B. Maure, F.-J. Rascόn, M. Lopez-Dupla, M. Ripoll, C. Lόpez González-Cobos, E. Fonseca, M. Akasbi, M. Pérez-de-Lis, I. Jiménez-Heredia, G. de la Red, A. Gato, M. Ramentol, A. Ruedas, B. Díaz-Lόpez, L. Pallarés, H. Gheitasi, M. Ramos-Casals
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To analyse the epidemiological, clinical and analytical features at diagnosis and the use of the European systemic activity index (ESSDAI) to predict the development of cancer in a large cohort of Spanish patients with primary Sjogren syndrome (SS). <h3>Methods</h3> The GEAS-SS multicenter registry was formed in 2005 with the aim of collecting a large series of Spanish patients with primary SS, and included thirteen Spanish reference centers with substantial experience in the management of SS patients. By January 2015, the database included 1216 consecutive patients fulfilling the 2002 classification criteria for primary SS. ESSDAI scores were retrospectively calculated at diagnosis. Disease activity states (DAS) were defined according to the baseline ESSDAI score (low DAS for an ESSDAI &lt;4, moderate DAS for an ESSDAI between 5 and 13, and high DAS for an ESSDAI higher than 13). Cancer was categorized as hematological or solid neoplasia. <h3>Results</h3> After a mean follow-up of 114 months, 84 (7%) patients developed solid cancer and 52 (4%) hematological neoplasia. The following baseline features at diagnosis were associated with the development of hematological neoplasia: male gender (19% vs 6%, p&lt;0.001), age at diagnosis (59 vs 54 yrs, p&lt;0.001), baseline systemic activity (75% vs 51%, p=0.001), neutropenia (19% vs 9%, p=0.028), C3 values &lt;0.82 g/L (19% vs 10%, p=0.048), C4 values &lt;0.07 g/L (24% vs 12%, p=0.02), monoclonal serum band (27% vs 8%, p&lt;0.001) and cryoglobulins (30% vs 9%, p&lt;0.001). In contrast, only age (59 vs 54 yrs, p&lt;0.001) and neutropenia (21% vs 9%, p=0.001) were related to the development of solid neoplasia. High systemic activity (high-DAS) was found in a higher frequency in patients who developed hematological in comparison with those who developed solid neoplasia or those without neoplasia (79% vs 24% vs 21%, p&lt;0.001). <h3>Conclusions</h3> Systemic and biological activity is closely related to the development of lymphoma in primary SS. Etiopathogenic factors such as B-cell hyperactivity and monoclonal, cryoglobulinemic-driven immunological responses have a dual effect, enhancing the risk of development of both systemic involvement and hematological neoplasia, but not the risk of solid neoplasia, whose development is independent of systemic Sjögren. <h3>Disclosure of Interest</h3> None declared
David Oliver: The department of spin
Authors: David Oliver
Journal: BMJ (2016)

Some say don’t shoot the messenger. The professionals leading government communications offices are simply politicians’ minions. I don’t believe that.

During the current crises in healthcare, ministers may be the lightning rod for our anger. But we need to stop letting the Department of Health’s press office off the hook, challenge and expose its partial truths. The messages it pumps out, inconvenient facts omitted, seep into the media and public consciousness and are often loaded against the services and professionals it claims to support. If you don’t believe me, check the @DeptHealthPress …
Closure of a large mucosal defect after endoscopic submucosal dissection using “pre-detached loop and clips” method with a single-channel gastroscope
Authors: Guan Lua, Feng Liu
Journal: Endoscopy (2015)

Endoscopic submucosal dissection (ESD) is commonly used for the treatment of early gastric neoplasms. However, there are reports indicating an increase in serious complications, such as perforation and delayed bleeding [1]. Various methods have been introduced to close the large mucosal defect after ESD, such as a simple closure method with metal clips or the "loop and clips" method [2]. Many authors prefer the loop and clips technique for closure of larger post-ESD mucosal defects, but this requires a two-channel endoscope and is technically more difficult. In this report, we describe a newly developed pre-detached loop technique as an easy and safe alternative method.
Comparison of the Yields of Several Selected Components in the Smoke From Different Tobacco Products
Authors: Dietrich Hoffmann, Gunter Rathkamp, Ernest L. Wynder
Journal: JNCI Journal of the National Cancer Institute (1963)

Smoke of a plain 85 mm cigarette, 2 types of cigars, a pipe with standard pipe tobacco, a pipe filled with cigarette tobacco, and a Syrian water pipe was analyzed for the mainstream particulate matter, nicotine, benzo[a]pyrene, and phenols. On the basis of equal weights of tobacco consumed, cigarettes gave the highest yields of both nicotine and particulate materials, with lesser amounts, in decreasing order, obtained from an American-type pipe, cigars, and an oriental water pipe. The highest value from 100 g tobacco for benzo[a]pyrene, 27.0 μg, and phenol, 68.7 mg, was found in the smoke of a pipe filled with standard pipe tobacco. A pipe filled with cigarette tobacco yielded benzo[a]pyrene, 10.5 μg, phenol, 21.2 mg; cigarette smoke, benzo[a]pyrene, 7.8 μg, phenol, 25.4 mg; cigar smoke, benzo[a]pyrene, 4.0 and 5.1 μg, phenol, 7.4 and 10.7 mg, with the lowest values for the smoke from an oriental water pipe, benzo[a]pyrene 1.7 μg, phenol, 1.8 mg. The water-filled oriental pipe retained about 90 percent of the phenol of the original smoke. Particulate matter, nicotine, and benzo[a]pyrene were retained to a lesser degree by the water (about 50%). Increased puff frequency resulted in higher yields of all 4 groups of compounds in the mainstream smoke. Values at 2 puffs per minute frequency ranged from 50 to 120 percent higher than those at 1 puff per minute when the other smoking factors were held constant. Since biological tests and comparisons of the carcinogenicity of the condensates of cigarettes, cigars, and pipes have previously been carried out on equal weights of condensate, the analytical results of this study were compared in the same manner. One g of the smoke condensates from 85 mm plain cigarettes, 2 types of cigars, and a standard pipe contain 1.25, 3.6, 3.9, and 6.0 μg benzo[a]pyrene, respectively. The corresponding phenol values were 4.1, 6.7, 8.2, and 15.0 mg per 1 g smoke condensate.
THU0329 Risk of Cancer is not Increased in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study
Authors: A. Singh, C. Crowson, M. Davis, H. Maradit-Kremers, E. Matteson, V. Chowdhary
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic immune dysregulation associated with chronic autoimmune diseases such as systemic lupus erythematosus (SLE) as well as immunomodulatory medications used for their treatment have been associated with an increased risk of malignancy. The pathogenesis of cutaneous lupus erythematosus (CLE) is similar to SLE. It is unclear whether CLE is associated with an increased risk of malignancy. <h3>Objectives</h3> We estimated the cumulative incidence of malignancy in a population-based cohort of patients with CLE, and compared the risk with an age- and sex-matched cohort without CLE. <h3>Methods</h3> Patients with subtypes of CLE (discoid, subacute cutaneous lupus, lupus panniculitis and bullous lupus) were identified from a population-based cohort in 1965-2005. Age- and sex-matched subjects without CLE were selected from the same population. Non-CLE subjects were assigned an index date corresponding to the CLE diagnosis date of the matched CLE patient. For a random sample of 66 of the 156 patients with CLE and the non-CLE subjects matched to them, data were collected on all cancers via medical record review. The cumulative incidence of cancer after CLE diagnosis was estimated using Kaplan–Meier methods. Cox models were used to estimate the relative risk of malignancy in patients with CLE as compared to non-CLE adjusted for age, sex and calendar year of index date. <h3>Results</h3> We identified 66 patients with CLE (mean age at time of CLE diagnosis, 55±14y; 64% females; 68% Caucasian; mean BMI, 27.3±7.2 kg/m<sup>2</sup>; 34.8% smokers), who were followed over a median follow-up of 12.0 years (interquartile range [IQR], 8.1-17.3y). Positive antinuclear antibody, anti-SSA and anti-SSB were seen in 48%, 47% and 18% of patients with CLE, respectively. Median ESR was 11 mm/hour (IQR, 4.0-25.0) and CRP 2.9 mg/dL (IQR 1.5-3.9). Overall, we observed 14 cases of incident cancer (including 5 cases of non-melanoma skin cancer). The cumulative 1-, 5- and 10-year incidence of any malignancy after diagnosis of CLE was 3.4%, 10.9% and 14.6%, respectively. As compared to age- and sex-matched non-CLE controls, the overall risk of malignancies was not increased in patients with CLE (hazard ratio [HR], 1.09; 95% CI, 0.51-2.37; p=0.81). The cumulative 1-, 5- and 10-year incidence of all malignancies except non-melanoma skin cancers in patients with CLE was 1.7%, 7.1% and 11.1%, respectively. As compared to matched controls, the risk of all malignancies except non-melanoma skin cancer in patients with CLE was not increased (HR, 0.88; 95% CI, 0.36-2.14; p=0.78). <h3>Conclusions</h3> The 10-year risk of any malignancy in a population-based cohort of patients with CLE is 14.6%. This risk is not increased as compared to age- and sex-matched subjects without CLE. <h3>Disclosure of Interest</h3> None declared